Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

被引:24
作者
Kolnagou, A [1 ]
Fessas, C
Papatryphonas, A
Economides, C
Kontoghiorghes, GJ
机构
[1] Paphos Gen Hosp, Thalassaemia Unit, Paphos, Cyprus
[2] Nicosia Heart Inst, Nicosia, Cyprus
[3] Makarios III Hosp, Dept Haematol, Nicosia, Cyprus
[4] Diagnost Ctr Agios Therissos, Nicosia, Cyprus
[5] Postgrad Res Inst Sci Technol Environm & Med, Limassol, Cyprus
关键词
D O I
10.1111/j.1365-2141.2004.05195.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:360 / 361
页数:2
相关论文
共 6 条
[1]   Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia [J].
Anderson, LJ ;
Wonke, B ;
Prescott, E ;
Holden, S ;
Walker, JM ;
Pennell, DJ .
LANCET, 2002, 360 (9332) :516-520
[2]   Purging iron from the heart [J].
Hershko, C ;
Cappellini, MD ;
Galanello, R ;
Piga, A ;
Tognoni, G ;
Masera, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (05) :545-551
[3]   Deferiprone versus desferrioxamine in thalassaemia, and T2*validation and utility - Reply [J].
Kontoghiorghes, GJ ;
Kolnagou, A .
LANCET, 2003, 361 (9352) :184-184
[4]   Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions - Comparison of epidemiological and therapeutic aspects with deferoxamine [J].
Kowoghiorghes, GJ ;
Neocleous, K ;
Koinagou, A .
DRUG SAFETY, 2003, 26 (08) :553-584
[5]   Ultrastructural pathology of the heart in patients with β-thalassaemia major [J].
Kyriacou, K ;
Michaelides, Y ;
Senkus, R ;
Simamonian, K ;
Pavlides, N ;
Antoniades, L ;
Zambartas, C .
ULTRASTRUCTURAL PATHOLOGY, 2000, 24 (02) :75-81
[6]   Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan [J].
Peng, CT ;
Chow, KC ;
Chen, JH ;
Chiang, YP ;
Lin, TY ;
Tsai, CH .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (06) :392-397